Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Collegium Pharmaceutical, Inc.

Collegium Reports Record Third Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Appoints Vikram Karnani as Chief Executive Officer
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Completes Acquisition of Ironshore Therapeutics
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Reports Second Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Participate in Jefferies Global Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Announces $35 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Reports First Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Announces CEO Transition
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Provides 2024 Financial Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Announces $25 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Reports Third Quarter 2023 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Announces $50 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Tickers COLL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.